Biopharma Firm Finalizes Takeover of French Immuno-Oncology Specialist
Transaction involving ImCheck Therapeutics enhances global company's cancer treatment portfolio.
The international biopharmaceutical corporation, Ipsen, successfully concluded its purchase of ImCheck Therapeutics on December 15, 2025, in Paris, France.
This deal formally incorporates the French, privately held biotechnology entity into Ipsen’s operations. ImCheck Therapeutics is recognized for its work in developing innovative, next-generation immunotherapies aimed at treating cancer.
The completion of this corporate action strategically strengthens Ipsen’s existing drug development programs in the field of oncology.
Ipsen functions as a global biopharmaceutical company focusing on three primary therapeutic areas: Oncology, Rare Disease, and Neuroscience. The corporation maintains a presence in over 40 countries, with global hubs in the U.S., France, and the U.K., and provides medicines to patients in more than 100 countries.
Source: https://uk.finance.yahoo.com/news/ipsen-completes-acquisition-imcheck-therapeutics-163000808.html
